6月23日,南京维立志博生物科技股份有限公司(简称维立志博)通过港交所聆讯,并披露更新后的招股说明书。招股说明书显示,2023年维立志博实现营业收入886.5万元,2024年及2025年一季度公司均无收入,净利润分别为-3.62亿元、-3.01亿元和-7536.7万元。对此,中国证券报记者电话采访维立志博相关人士,维立志博方面回应称,目前公司生产经营没有异常,各个职能部门都是正常运行的,具体情况以...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.